Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hansoh Expands Merigolix use with ART Development Initiation
Details : HS-10518 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated for improvement of pregnancy rate per cycle.
Product Name : HS-10518
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HS-10535
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : $2,012.0 million
Deal Type : Licensing Agreement
Merck Signs Up to $2 Bln Obesity Drug Deal with Chinese Biotech Hansoh
Details : Under the agreement, Hansoh has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
Product Name : HS-10535
Product Type : Other Small Molecule
Upfront Cash : $112.0 million
December 18, 2024
Lead Product(s) : HS-10535
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : $2,012.0 million
Deal Type : Licensing Agreement
Hansoh’s HS-20093 Shows Potential in Second-Line SCLC Therapy in China
Details : HS-20093 is a novel B7-H3-targeted ADC composed of a fully-humanized anti-B7-H3 monoclonal antibody covalently linked to TOPOi payload and being developed in China for small cell lung cancer.
Product Name : HS-20093
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 22, 2024
GSK Enters Exclusive License Agreement with Hansoh for HS-20093
Details : Under the agreement, GSK will obtain exclusive worldwide rights to progress development and commercialisation for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilising a clinically validated topoisomerase inhibitor (TOPOi) payload, in advanc...
Product Name : HS-20093
Product Type : Other Large Molecule
Upfront Cash : $185.0 million
December 20, 2023
GSK Enters Exclusive License Agreement with Hansoh for HS-20089
Details : Under the agreement, GSK will obtain rights to progress development and commercialisation for HS-20089, a B7-H4 targeted antibody-drug conjugate currently in phase I clinical trials in China, in ovarian and endometrial cancer.
Product Name : HS-20089
Product Type : Other Large Molecule
Upfront Cash : $85.0 million
October 20, 2023
Lead Product(s) : Aumolertinib Mesylate,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.
Product Name : Ameile
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Aumolertinib Mesylate,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aumolertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : EQRx
Deal Size : Undisclosed
Deal Type : Collaboration
Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib
Details : Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).
Product Name : Ameile
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
July 23, 2020
Lead Product(s) : Aumolertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : EQRx
Deal Size : Undisclosed
Deal Type : Collaboration